## Note
nid: 1489968446315
model: AnKingOverhaul
tags: #AK_Original_Decks::Step_1::Zanki_Pharmacology, #AK_Step1_v11::#B&B::12_Immunology::03_Pharm::02_Immunosuppressive_Drugs, #AK_Step1_v11::#FirstAid::02_Immunology::04_Immunosuppressants::01_Immunosuppressants, #AK_Step1_v11::#FirstAid::02_Immunology::04_Immunosuppressants::01_Immunosuppressants::Etanercept, #AK_Step1_v11::#FirstAid::11_Musculoskeletal_Skin_Connective_Tissue::04_Pharm::10_TNF-a_inhibitors, #AK_Step1_v11::#FirstAid::11_Musculoskeletal_Skin_Connective_Tissue::04_Pharm::10_TNF-a_inhibitors::Etanercept, #AK_Step1_v11::#OME::07_Immunology::16_Immunosuppression, #AK_Step1_v11::#OME_banner::Clinical::08_Rheumatology::03_Rheumatoid_Arthritis, #AK_Step1_v11::#Physeo::09_Pharm::09_Musculoskeletal::09_TNF-alpha_Inhibitors, #AK_Step1_v11::#Pixorize::01_Immunology::05_Cytokines::01_TNF-alpha, #AK_Step1_v11::#Pixorize::03_Pharm::12_MSK::Etanercept, #AK_Step1_v11::#Pixorize::03_Pharm::12_MSK::TNF_Inhibitors_(Infliximab,_Adalimumab._Certolizumab,_Golimumab), #AK_Step1_v11::#SketchyPharm::Immunology-&-Biochemistry-Pharmacology::Immuno-suppressives::General-Immunotherapy, #AK_Step1_v11::#UWorld::1000-9999::8000-8999::8523, #AK_Step1_v11::^Other::^EXPN, #AK_Step1_v11::^Other::^HighYield::1-HighYield, #AK_Step2_v11::#OME::08_Rheumatology::03_Rheumatoid_Arthritis, #AK_Step2_v11::#Resources_by_rotation::IM::ome::rheum::ra, #AK_Step2_v11::Original_decks::Dorian::im::ome::rheum::ra
markdown: false

### Text
<div>
  <b>{{c2::Etanercept}}</b> is a <u>decoy</u> <b>soluble
  receptor</b> that binds <b>{{c1::TNF-a}}</b>
</div>

### Extra
Etanercept is NOT a monoclonal antibody

### Lecture Notes


### Missed Questions


### Pathoma


### Boards and Beyond


### First Aid
<img src="paste-26e37ee974d7adce9e47d1d8f7a93d94f6b18ce4.jpg">

### Sketchy


### Pixorize


### Physeo


### OME
<div class="ome-widget">
  <a href=
  "https://onlinemeded.org/spa/rheumatology/rheumatoid-arthritis/acquire?ref=anki">
  <img src="_OME_AnkiFlashcards_Lesson_3.png"></a>
</div>

### Additional Resources


### One by one

